BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-01

193 industry Phase 2/3 trial readout(s) and 29 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-12 | 2025-02 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-01-03Complete response lettercomplete responseOWP Pharmaceuticals, Inc.suspensionCRL 2025-01-03: OWP Pharmaceuticals, Inc. NDA 218879 ((lamotrigine) oral suspension)
2025-01-03Complete response lettercomplete responseTanvex BioPharma USA, Inc.CRL 2025-01-03: Tanvex BioPharma USA, Inc. BLA 761266
2025-01-10FDA AdComheldSeikagaku Corp.AdCom 2025-01-10: Anesthetic and Analgesic Drug Products Advisory Committee - BLA 761393
2025-01-15Complete response lettercomplete responseAtara Biotherapeutics, Inc. ATRAtabelecleucel®) @) , 4CRL 2025-01-15: Atara Biotherapeutics, Inc. BL 125745 (tabelecleucel®) @) , 4)
2025-01-15FDA approvalapprovedELI LILLY AND CO LLYOMVOHApproved 2025-01-15: OMVOH (BLA761279 SUPPL2)
2025-01-15FDA approvalapprovedELI LILLY AND CO LLYOMVOHApproved 2025-01-15: OMVOH (BLA761279 SUPPL3)
2025-01-16FDA approvalapprovedASTRAZENECA AZNCALQUENCEApproved 2025-01-16: CALQUENCE (NDA210259 SUPPL11)
2025-01-16FDA approvalapprovedAMGEN AMGNVECTIBIXApproved 2025-01-16: VECTIBIX (BLA125147 SUPPL213)
2025-01-16FDA approvalapprovedAMGEN INC AMGNLUMAKRASApproved 2025-01-16: LUMAKRAS (NDA214665 SUPPL9)
2025-01-16FDA approvalapprovedASTRAZENECA AZNCALQUENCEApproved 2025-01-16: CALQUENCE (NDA216387 SUPPL5)
2025-01-16FDA approvalapprovedAZURITYBRYNOVINApproved 2025-01-16: BRYNOVIN (NDA219122 ORIG1)
2025-01-17Complete response lettercomplete responseHospira, Inc.CRL 2025-01-17: Hospira, Inc. NDA 219112
2025-01-17FDA approvalapprovedJANSSEN PHARMSSPRAVATOApproved 2025-01-17: SPRAVATO (NDA211243 SUPPL16)
2025-01-17FDA approvalapprovedDAIICHI SANKYO INCDATROWAYApproved 2025-01-17: DATROWAY (BLA761394 ORIG1)
2025-01-21FDA approvalapprovedMEDEXUSGRAFAPEXApproved 2025-01-21: GRAFAPEX (NDA214759 ORIG1)
2025-01-23FDA approvalapprovedJANSSEN BIOTECHDARZALEXApproved 2025-01-23: DARZALEX (BLA761036 SUPPL51)
2025-01-24FDA approvalapprovedEISAI INCLEQEMBIApproved 2025-01-24: LEQEMBI (BLA761269 SUPPL5)
2025-01-24FDA approvalapprovedCELLTRION INCAVTOZMAApproved 2025-01-24: AVTOZMA (BLA761420 ORIG1)
2025-01-27FDA approvalapprovedELI LILLY AND CO LLYCYRAMZAApproved 2025-01-27: CYRAMZA (BLA125477 SUPPL48)
2025-01-27FDA approvalapprovedDAIICHI SANKYOENHERTUApproved 2025-01-27: ENHERTU (BLA761139 SUPPL32)
2025-01-28FDA approvalapprovedNOVO NVOOZEMPICApproved 2025-01-28: OZEMPIC (NDA209637 SUPPL25)
2025-01-28FDA approvalapprovedBRISTOL MYERS SQUIBB BMYYERVOYApproved 2025-01-28: YERVOY (BLA125377 SUPPL132)
2025-01-28FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-01-28: KEYTRUDA (BLA125514 SUPPL172)
2025-01-28FDA approvalapprovedNOVITIUM PHARMAINZIRQOApproved 2025-01-28: INZIRQO (NDA219141 ORIG1)
2025-01-29FDA approvalapprovedEISAI INCLENVIMAApproved 2025-01-29: LENVIMA (NDA206947 SUPPL33)
2025-01-30FDA approvalapprovedVERTEX PHARMS INC VERXJOURNAVXApproved 2025-01-30: JOURNAVX (NDA219209 ORIG1)
2025-01-30FDA approvalapprovedAXSOME AXSMSYMBRAVOApproved 2025-01-30: SYMBRAVO (NDA215431 ORIG1)
2025-01-31Complete response lettercomplete responseSFJ Pharmaceuticals, Inc.We have completed our review of this application, as amendedCRL 2025-01-31: SFJ Pharmaceuticals, Inc. BLA 761290 (We have completed our review of this application, as amended)
2025-01-31FDA approvalapprovedPFIZER PFEPAXLOVID (COPACKAGED)Approved 2025-01-31: PAXLOVID (COPACKAGED) (NDA217188 SUPPL8)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-01 est.P1/P2US Oncology ResearchNCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerBreast Neoplasms; Malignant Neoplasm of Breastactive not recruiting34
2025-01 est.P2Allievex CorporationNCT03784287 A Treatment Extension Study of Mucopolysaccharidosis Type IIIBMucopolysaccharidosis Type IIIB; MPS III Bunknown20
2025-01 est.P3Advicenne PharmaNCT03831152 Extension Study in Primary Distal Renal Tubular AcidosisAcidosis, Renal Tubularwithdrawn
2025-01 est.P3Dr. Falk Pharma GmbHNCT03872921 norUrsodeoxycholic Acid vs Placebo in PSCPrimary Sclerosing Cholangitisunknown303
2025-01 est.P2RedHill Biopharma Limited RDHLNCT04027894 Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 YearsTraveler's Diarrheaunknown142
2025-01 est.P2Andover Eye AssociatesNCT04296864 Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)Atopic Keratoconjunctivitisunknown42
2025-01 est.P3EMSNCT04970108 Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and HypertensionHypertension Associated; Type II Diabetes Mellituswithdrawn
2025-01 est.P2Dr. Falk Pharma GmbHNCT05083390 Norursodeoxycholic Acid vs. Placebo in NASHNonalcoholic Steatohepatitisunknown363
2025-01 est.P2R-Pharm International, LLCNCT05092776 Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or IntoFamilial Mediterranean Fever; FMFactive not recruiting84
2025-01 est.P1/P2Nuvation Bio Inc. NUVBNCT05191017 Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCProstate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Cawithdrawn
2025-01 est.P3Moberg Pharma ABNCT05279846 A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)Onychomycosisunknown350
2025-01 est.P1/P2Shanghai Vitalgen BioPharma Co., Ltd.NCT05441553 A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B PatientsHemophilia Bunknown26
2025-01 est.P3EMSNCT05456152 Safety and Efficacy of Zolpidem in the Long-Term Treatment of InsomniaChronic Insomniaunknown358
2025-01 est.P2Shanton Pharma Pte. Ltd.NCT05690204 Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.Goutactive not recruiting87
2025-01 est.P3BiocadNCT05730699 Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)Neuromyelitis Optica Spectrum Disordersactive not recruiting105
2025-01 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05774340 A Study of CM326 in Subjects With Moderate to Severe AsthmaModerate to Severe Asthmaunknown207
2025-01 est.P3ReFlow Medical, Inc.NCT05848232 Single-Arm Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total OcclusionsCoronary Occlusionunknown150
2025-01 est.P3Daewoong Pharmaceutical Co. LTD.NCT06121830 Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)Non-erosive Reflux Disease; Non-Erosive Gastro-Esophageal Reflux Disease; Non-Erosive Esophageal Refunknown324
2025-01 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06279286 Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia DisorderInsomnia Disorderunknown312
2025-01 est.P3BiocadNCT06296121 A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaMultiple Myelomaunknown252
2025-01 est.P2Luye Pharma Group Ltd.NCT06467409 Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic SurgeryPain, Postoperativeunknown150
2025-01-01 est.P3Zai Lab (Hong Kong), Ltd.NCT06162286 A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABPCommunity-acquired Bacterial Pneumoniaunknown100
2025-01-01P1/P2Valerio TherapeuticsNCT06257758 A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid TumorsAdvanced or Metastatic Solid Tumors; Breast Cancer; Recurrent Ovarian Cancer; Prostate Cancerterminated6
2025-01-01P3Laboratorios Silanes S.A. de C.V.NCT06516094 Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic PainChronic Low-back Paincompleted192
2025-01-02P3Vor Biopharma VORNCT06456567 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)Systemic Lupus Erythematosuswithdrawn
2025-01-02P2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06545500 A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDChronic Obstructive Pulmonary Diseasecompleted46
2025-01-03P1/P2Sun Pharma Advanced Research Company LimitedNCT02629692 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesHealthy (For Part A); Chronic Myeloid Leukemia (for Part B and C)terminated124
2025-01-03P2Boehringer IngelheimNCT05213624 A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental GlomerulosclerosisKidney Disease, Chroniccompleted67
2025-01-03P2Chipscreen Biosciences, Ltd.NCT05497843 Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)Soft Tissue Sarcomacompleted40
2025-01-03P2Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SANCT06001177 A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac DiseaseCeliac Disease; Coeliac Diseasecompleted55
2025-01-03P1/P2Immunwork, Inc.NCT06471530 A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without DiabetesOverweight and Obesitycompleted38
2025-01-03P1/P2Metsera, a wholly owned subsidiary of PfizerNCT06857617 This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or ObesityObesity and Overweightcompleted120
2025-01-04P3Bharat Biotech International LimitedNCT06200844 The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean InfantsRotavirus Infection of Childrenactive not recruiting5800
2025-01-04P2Response PharmaceuticalsNCT06640972 Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 AgonistsTriglycerides; Weight Gain Trajectory; Cholesterol, Elevatedcompleted68
2025-01-06P1/P2Takeda TAKNCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsPancreatic Cancer; Hepatocellular Cancer; Mesothelioma; Breast Cancer; Gastric Cancer; Esophageal Caterminated61
2025-01-06P3Vor Biopharma VORNCT05306574 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)Systemic Lupus Erythematosusterminated91
2025-01-06P2Trevi Therapeutics TRVINCT05962151 Refractory Chronic Cough Improvement Via NAL ER (RIVER)Refractory Chronic Coughcompleted66
2025-01-06P1/P2Daiichi SankyoNCT05979831 A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton SyndromeNetherton Syndrometerminated9
2025-01-06P3Novo Nordisk A/S NVONCT05996848 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightObesity or Overweightcompleted300
2025-01-06P3Shanghai Ark Biopharmaceutical Co., Ltd.NCT06359899 A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHDADHDcompleted55
2025-01-07P1/P2MedivirNCT03781934 A Study to Evaluate MIV-818 in Patients With Liver Cancer ManifestationsHepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastasescompleted53
2025-01-07P1/P2Advanced Accelerator ApplicationsNCT03872778 [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion UptakeNeoplasmscompleted35
2025-01-07P3Merck Sharp & Dohme LLC MRKNCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOGUterine Cervical Neoplasmscompleted1060
2025-01-07P3Janssen Research & Development, LLCNCT04497844 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With DelProstatic Neoplasmsactive not recruiting696
2025-01-07P1/P2Kronos BioNCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)Relapsed Solid Tumors; Refractory Solid Tumors; Non-Hodgkin Lymphoma; HGSOC; Platinum Resistant Highterminated135
2025-01-07 est.P2Immunic AG IMUXNCT05054140 Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisMultiple Sclerosisunknown450
2025-01-07P3Incyte Corporation INCYNCT05620836 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa (HS)completed619
2025-01-08P1/P2BioAtla, Inc. BCABNCT03425279 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaUndifferentiated Pleomorphic Sarcoma; Myxofibrosarcomacompleted245
2025-01-08P3Amgen AMGNNCT03832998 Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineMigrainecompleted284
2025-01-08P3BeiGeneNCT03957590 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal SquamouEsophageal Squamous Cell Carcinoma (ESCC)completed370
2025-01-08P1/P2Ultragenyx Pharmaceutical Inc RARENCT04259281 A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeAngelman Syndromecompleted74
2025-01-08P3Mural Oncology, IncNCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancerterminated456
2025-01-08 est.P2/P3SMT bio Co., Ltd.NCT05429697 Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract CancerBiliary Tract Cancerunknown128
2025-01-08 est.P3Azidus BrasilNCT06089122 Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIGPrimary Immunodeficiency Diseaseunknown50
2025-01-08P1/P2Norroy Bioscience Co., LTDNCT06389682 Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in PatientsClear Cell Renal Cell Carcinoma Metastaticcompleted19
2025-01-09P1/P2Constellation Pharmaceuticals CEGNCT02158858 A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesMyelofibrosis; Leukemia, Myelocytic, Acute; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplacompleted336
2025-01-09P2/P3Rhythm Pharmaceuticals, Inc. RYTMNCT03651765 Long Term Extension Trial of SetmelanotideObesity Associated With Defects in Leptin-melanocortin Pathwaycompleted205
2025-01-09P1/P2Hookipa Biotech GmbHNCT04180215 A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other CancersHPV-Related Squamous Cell Carcinomacompleted198
2025-01-09P1/P2Lyell Immunopharma, Inc. LYELNCT06153095 A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus; Lupus Nephritiswithdrawn
2025-01-09P2Innovent Biologics (Suzhou) Co. Ltd.NCT06525506 A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseThyroid Eye Diseasecompleted38
2025-01-09 est.P1/P2Intellia Therapeutics NTLANCT06622668 NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseLung Disease; Pulmonary Disease; AATD; Alpha-1 Antitrypsin Deficiency; Alpha-1 Antitrypsin Deficiencwithdrawn
2025-01-10P2ChemomAb Ltd. CMMBNCT04595825 CM-101 in PSC Patients -The SPRING StudyPrimary Sclerosing Cholangitiscompleted77
2025-01-10P2NovoCure GmbH NVCRNCT04892472 EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment ofNon-small Cell Lung Cancerterminated15
2025-01-10P1/P2LaNova Medicines Zhejiang Co., Ltd.NCT05161390 Study of LM-302 in Patients With Advance Solid TumorsAdvanced Solid Tumorcompleted153
2025-01-10P3Immunovant Sciences GmbH IMVTNCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia GravisGeneralized Myasthenia Gravisterminated233
2025-01-10P1/P2Shanxi Kangbao Biological Product Co., Ltd.NCT06560489 Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected PatientsHivcompleted40
2025-01-13P3Novartis Pharmaceuticals NVSNCT04720157 An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in AProstatic Neoplasmsactive not recruiting1144
2025-01-13P2Celon Pharma SANCT05297201 Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced DyskinesiaParkinson Disease; Dyskinesia, Medication-Inducedcompleted105
2025-01-13P3Emalex Biosciences Inc.NCT05615220 Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and AdultsTourette Disordercompleted216
2025-01-13P2/P3Boehringer IngelheimNCT05856526 A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton SyndromeNetherton Syndrometerminated43
2025-01-13P1/P2Evopoint Biosciences Inc.NCT06022757 Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)Carcinoma; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Prostate Cancer; Small-ceterminated12
2025-01-13P2Aardvark Therapeutics, Inc. AARDNCT06126653 A Study to Evaluate ARD-501 in Patients With Autism Spectrum DisorderAutism Spectrum Disordercompleted5
2025-01-13P2Bigespas LTDNCT06292351 DMB-I in the Treatment of Alzheimer Type DementiaAlzheimer Disease; Dementia of Alzheimer Typecompleted133
2025-01-14P1/P2Sarepta Therapeutics, Inc. SRPTNCT03652259 Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-SarcoglycanLimb-Girdle Muscular Dystrophy, Type 2Eterminated6
2025-01-14P3BioMarin Pharmaceutical BMRNNCT05270837 Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaPhenylketonuria (PKU)active not recruiting55
2025-01-14P1/P2Inmagene LLCNCT06060977 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata ParticipantsAlopecia Areata (AA)completed29
2025-01-14P2Lexicon Pharmaceuticals LXRXNCT06203002 A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)Diabetic Peripheral Neuropathic Paincompleted496
2025-01-14P3Janssen Pharmaceutical K.K.NCT06295692 A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisGeneralized Pustular Psoriasis; Erythrodermic Psoriasisactive not recruiting19
2025-01-14P3Avexima Diol LLCNCT07124819 Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to EnoxaparinArthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Venous Thromboembolism (VTE); Prevecompleted215
2025-01-15P2Gilead Sciences GILDNCT03964727 Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsMetastatic Solid Tumoractive not recruiting227
2025-01-15P3Hoffmann-La RocheNCT04035005 A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisMultiple Sclerosis, Primary Progressiveactive not recruiting1013
2025-01-15P3Saving Patients' Lives Medical B.V.NCT04261777 Ferumoxtran-10-enhanced MRI in Prostate Cancer PatientsProstate Cancer; Metastasis; Prostatectomyterminated172
2025-01-15P3Principia Biopharma, a Sanofi CompanyNCT04562766 Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)Immune Thrombocytopeniacompleted232
2025-01-15P2Miltenyi Biomedicine GmbHNCT04844866 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsDiffuse Large B-cell Lymphomarecruiting213
2025-01-15P3Mylan Technologies Inc.NCT05139121 Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesContraceptioncompleted1320
2025-01-15P2Eli Lilly and Company LLYNCT05440786 CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's SarcomaSarcoma, Ewing; Neoplasm Metastasisactive not recruiting46
2025-01-15P1/P2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT05580770 Mirdametinib + BGB-3245 in Advanced Solid TumorsAdvanced Solid Tumorterminated23
2025-01-15P3GlaxoSmithKlineNCT05705440 A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies DRespiratory Syncytial Virus Infectionscompleted3855
2025-01-15P2Mineralys Therapeutics Inc. MLYSNCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenHypertensioncompleted285
2025-01-15P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05849727 A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid ArthritisRheumatoid Arthritisterminated195
2025-01-15P2/P3Biohaven Therapeutics Ltd. BHVNNCT06419582 BHV-7000 Acute Treatment of Bipolar ManiaBipolar Disordercompleted274
2025-01-15P2TAHO Pharmaceuticals Ltd.NCT06689436 Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy VolunteersRandom Allocation; Intermittent Fasting; Enteral Feedingcompleted60
2025-01-16P2Gilead Sciences GILDNCT05281510 Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenHIV-1-infectioncompleted20
2025-01-16P3Novo Nordisk A/S NVONCT05890976 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)Overweight; Obesitycompleted200
2025-01-16P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06527144 A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructivecompleted240
2025-01-16P1/P2Beijing Mabworks Biotech Co., Ltd.NCT07044115 Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus NephritisLupus Nephritisactive not recruiting41
2025-01-17P1/P2Great Novel Therapeutics Biotech & Medicals CorporationNCT05770882 Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)terminated7
2025-01-17P3Novo Nordisk A/S NVONCT05813925 A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightObesity or Overweightcompleted331
2025-01-17P3Kowa Research Institute, Inc.NCT05826353 A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs EndothelialFuchs Endothelial Corneal Dystrophycompleted110
2025-01-17P3Ferring PharmaceuticalsNCT05831189 A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Clostridium Difficile Infection Recurrencecompleted41
2025-01-17 est.P1/P2Shanton Pharma Pte. Ltd.NCT06729853 PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal FunctionGout; Hyperuricemiaactive not recruiting32
2025-01-20P2Novartis Pharmaceuticals NVSNCT04952753 Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRCMetastatic Colorectal Cancerterminated202
2025-01-20P1/P2PT. Prodia Stem Cell IndonesiaNCT05279768 Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.Polycystic Ovary Syndromecompleted44
2025-01-20P3Supernus Pharmaceuticals, Inc. SUPNNCT05655520 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseHuntington's Diseaseterminated153
2025-01-20P2Guangdong Hengrui Pharmaceutical Co., LtdNCT05847920 Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA NephropathyPrimary IgA Nephropathyterminated53
2025-01-20P3Laboratorios Silanes S.A. de C.V.NCT06531707 Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus LoratadineCommon Coldcompleted177
2025-01-21P3Chiesi Farmaceutici S.p.A.NCT03566017 Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseaseFabry Diseasecompleted97
2025-01-21P2Genentech, Inc.NCT03815058 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Advanced Melanomacompleted131
2025-01-21P2Navitor Pharmaceuticals, Inc.NCT05066672 Phase 2 Study of NV-5138 in Adults With Treatment Resistant DepressionTreatment Resistant Depressioncompleted250
2025-01-21P2Rivus Pharmaceuticals, Inc.NCT05979779 Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Fatty Liveractive not recruiting219
2025-01-21P2Unity Biotechnology, Inc.NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)Diabetic Macular Edema; Retinal Disease; Macular Edema; Diabetes Mellitus; Diabetic Retinopathy; Retcompleted52
2025-01-21P1/P2Wuhan YZY Biopharma Co., Ltd.NCT06266143 A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic CancerAdvanced Pancreatic Adenocarcinomacompleted71
2025-01-21P1/P2Sutro Biopharma, Inc. STRONCT06679582 Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLAcute Myeloid Leukemia (AML)terminated1
2025-01-22P3Ethicon, Inc.NCT03255174 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding StudyControlling Mild to Moderate Bleeding During Surgerycompleted35
2025-01-22P1/P2Xantho Biotechnology Co., LTDNCT04369846 A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis PatientsAtopic Dermatitiscompleted76
2025-01-22P3Novartis Pharmaceuticals NVSNCT04940052 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V6Differentiated Thyroid Cancer (DTC)active not recruiting153
2025-01-22P2Tasly Pharmaceutical Group Co., LtdNCT04944706 Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection FractionChronic Heart Failure With Preserved Ejection Fractioncompleted225
2025-01-22P2Lumos PharmaNCT05250063 Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)Growth Hormone Deficiencycompleted15
2025-01-22P2Eli Lilly and Company LLYNCT05592275 A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure; Heart Failure With Preserved Ejection Fractionterminated332
2025-01-22P210xBio, LLCNCT05760248 Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank AdipositySubcutaneous Fat Disordercompleted13
2025-01-22P3Takeda TAKNCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentPlaque Psoriasiscompleted693
2025-01-22P2Eli Lilly and Company LLYNCT06124807 A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity; Overweight and Obesitycompleted179
2025-01-22P2Shandong Suncadia Medicine Co., Ltd.NCT06250946 Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .Overweight and Obesitycompleted235
2025-01-23P3EMSNCT03540355 Efficacy and Safety of Cipros 20 Association on Dyslipidemia TreatmentDyslipidemiascompleted406
2025-01-23P2Ironwood Pharmaceuticals, Inc. IRWDNCT05740007 A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis; Bladder Pain Syndrometerminated98
2025-01-23P1/P2STCube, Inc.NCT06016270 A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung Cancerterminated10
2025-01-23P3Keymed Biosciences Co.LtdNCT06277765 Study of CM310 Injection in Adolescent Subjects With Atopic DermatisAtopic Dermatitiscompleted180
2025-01-23P3Tonghua Dongbao Pharmaceutical Co.,LtdNCT07282054 Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 DiabetesType 1 Diabetescompleted550
2025-01-24P1/P2Clarity Pharmaceuticals LtdNCT04023331 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory NeuroblastomaNeuroblastoma; Relapsed Neuroblastoma; Refractory Neuroblastomaterminated21
2025-01-24P2Ionis Pharmaceuticals, Inc. IONSNCT04307381 An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaHereditary Angioedemacompleted20
2025-01-24P2BeiGeneNCT05479994 Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaLeukemia; Lymphoma; Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphoactive not recruiting100
2025-01-24P1/P2Centessa Pharmaceuticals (UK) LimitedNCT05821777 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid TumorsAdvanced Solid Tumorterminated25
2025-01-24 est.P3Novo Nordisk A/S NVONCT06083675 Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesDiabetes Mellitus, Type 2withdrawn
2025-01-24P2Haisco Pharmaceutical Group Co., Ltd.NCT07442877 A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPostoperative Pain Managementcompleted161
2025-01-25P2Mina Alpha LimitedNCT04710641 Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib AloneHepatocellular Carcinoma; Hepatitis B; Hepatitis Ccompleted8
2025-01-26P2Bridge Biotherapeutics, Inc.NCT05483907 To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPFIdiopathic Pulmonary Fibrosiscompleted129
2025-01-27P3AstraZeneca AZNNCT03534453 Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyRelapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platcompleted225
2025-01-27P1/P2Loxo Oncology, Inc.NCT03740529 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLChronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymcompleted803
2025-01-27P3Hoffmann-La RocheNCT04222972 A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Trterminated223
2025-01-27P2Merck Sharp & Dohme LLC MRKNCT04704219 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)Renal Cell Carcinomacompleted160
2025-01-27P2Bristol-Myers Squibb BMYNCT05197426 A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese ParticipAcute Myeloid Leukemiaactive not recruiting19
2025-01-27P2Neurocrine Biosciences NBIXNCT05301894 Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepEpileptic Encephalopathy; Continuous Spike and Wave During Sleepterminated19
2025-01-27P2Kite, A Gilead CompanyNCT05537766 Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesRelapsed/Refractory Waldenstrom Macroglobulinemia; Relapsed/Refractory Richter Transformation; Relapterminated19
2025-01-27P3Spero Therapeutics SPRONCT06059846 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract InfectionUrinary Tract Infection; Acute Pyelonephritiscompleted1690
2025-01-27P3Jiaxing AnDiCon Biotech Co.,LtdNCT06507813 Safety and Efficacy of ADC189 in Children 2-11 Years Old With InfluenzaInfluenza Type A; Influenza Type Bcompleted190
2025-01-27P3Alcon Research ALCNCT06538662 An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsOcular Redness; Eye Irritationcompleted284
2025-01-27P2Beijing Supreme Life Pharmaceutical Technology Co., Ltd.NCT06575478 Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes PatientsDiabetes Mellitus, Type 2; Diabetes; Type2diabetescompleted95
2025-01-28P3Zealand Pharma ZEAL.CONCT03941236 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismCongenital Hyperinsulinismcompleted42
2025-01-28P2Sermonix Pharmaceuticals Inc.NCT04432454 Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationMetastatic Breast Cancercompleted29
2025-01-28P3Jazz Pharmaceuticals JAZZNCT04485104 Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut SyndrSeizure in Participants With Tuberous Sclerosis Complex; Seizure in Participants With Dravet Syndromterminated3
2025-01-28P3Novartis Pharmaceuticals NVSNCT05305664 A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients WiHyperlipoproteinemia(a)completed51
2025-01-28P3Novo Nordisk A/S NVONCT05394519 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightOverweight; Obesity; Type 2 Diabetes Mellituscompleted1200
2025-01-28P1/P2Advagene Biopharma Co. Ltd.NCT05985694 AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic AsthmaEosinophilic Asthmacompleted40
2025-01-28P3UCB Biopharma SRLNCT06471361 A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted31
2025-01-28P3Sanofi Pasteur, a Sanofi Company SNYNCT06641180 Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgeInfluenzacompleted1180
2025-01-29P2Xynomic Pharmaceuticals, Inc.NCT03934567 A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaLymphoma, Follicularactive not recruiting87
2025-01-29P3AbbVie ABBVNCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult ParticipantMyelofibrosis (MF)active not recruiting330
2025-01-29P1/P2OnKure, Inc. OKURNCT05340621 NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)RAS Mutation; NRAS Gene Mutation; Melanomacompleted36
2025-01-29P3Amgen AMGNNCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)active not recruiting509
2025-01-29P3ApcinteX LtdNCT06568302 The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical TrialHemophilia a; Hemophilia B; Hemophilia a with Inhibitor; Hemophilia B with Inhibitorterminated15
2025-01-30P2/P3Pharming Technologies B.V. PHARNCT02859727 Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLIActivated PI3Kdelta Syndrome (APDS); PASLI Diseaseterminated37
2025-01-30P3Baxalta now part of ShireNCT03879135 A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)Von Willebrand Disease (VWD)completed38
2025-01-30P2Merck Sharp & Dohme LLC MRKNCT04564547 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus TyHIV-1 Infectioncompleted161
2025-01-30P2Hoffmann-La RocheNCT04785820 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of thAdvanced or Metastatic Esophageal Squamous Cell Carcinomacompleted190
2025-01-30P2Adaptive Phage Therapeutics, Inc.NCT05177107 Bacteriophage Therapy in Patients With Diabetic Foot OsteomyelitisOsteomyelitis; Diabetic Foot Osteomyelitisterminated41
2025-01-30 est.P1/P2Inmunotek S.L.NCT05208060 Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood CellsImmune Responseunknown48
2025-01-30P3RDC Clinical Pty LtdNCT05795816 Effectiveness of Testofen Compared to Placebo on Long COVID SymptomsLong Covid19completed150
2025-01-30P2/P3Atom Therapeutics Co., LtdNCT05818085 Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With GoutGoutcompleted300
2025-01-30P2Cerevance Beta, Inc.NCT06006247 Early Parkinson's Disease Monotherapy With CVN424Parkinson's Diseasecompleted64
2025-01-30 est.P2Huabo Biopharm Co., Ltd.NCT06222125 A Study of HB0025 Injection in Patients With Advanced Renal CancerRenal Cancerunknown100
2025-01-30 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06299982 An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsOPlaque Psoriasis Patientsunknown750
2025-01-30 est.P3AkesoNCT06383468 A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic DermatitisAtopic Dermatitisunknown420
2025-01-30 est.P2DHA Coffee Co., LtdNCT06489860 SARS-CoV-2 Safety Study for the Treatment of COVID-19SARS-CoV-2withdrawn
2025-01-30P3Alcon Research ALCNCT06544707 A Study Designed to Evaluate Tear ProductionDry Eye Diseasecompleted81
2025-01-30P2Novartis Pharmaceuticals NVSNCT07235020 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum MalariaUncomplicated Plasmodium Falciparum Malariacompleted52
2025-01-31P1/P2AstraZeneca AZNNCT04538742 A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerMetastatic Breast Canceractive not recruiting245
2025-01-31 est.P3Hoffmann-La RocheNCT05126966 A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects WithNeovascular Age-Related Macular Degenerationwithdrawn
2025-01-31P2Spruce Biosciences SPRBNCT05128942 A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHCongenital Adrenal Hyperplasia; 21-OHDterminated67
2025-01-31P2Cardiol Therapeutics Inc. CRDLNCT05180240 Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisAcute Myocarditiscompleted109
2025-01-31P3Cassava Sciences, Inc.NCT05575076 Open-label Extension for Phase 3 Clinical Trials of SimufilamAlzheimer Diseaseterminated1081
2025-01-31P3Pfizer PFENCT05654623 A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerAdvanced Breast Canceractive not recruiting624
2025-01-31 est.P2Ascension HealthNCT05691959 Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular ResponseAtrial Fibrillation With Rapid Ventricular Response; Hypotensionunknown378
2025-01-31P2BioCryst Pharmaceuticals BCRXNCT05741346 Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuriaterminated28
2025-01-31P2Alector Inc. ALECNCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseAlzheimer's Diseaseterminated197
2025-01-31P3Intuitive Surgical ISRGNCT05954767 IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological SurgeryUreter Injurycompleted189
2025-01-31P2Inspirna, Inc.NCT05983367 A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal CancerColorectal Cancer; Metastatic Colon Cancerterminated76
2025-01-31 est.P2Monyan Pharmaceutical (Shanghai) Co., Ltd.NCT06092606 A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer PatientsCancer; Heart Failure; Arrhythmia; Doxorubicin Induced Cardiomyopathy; Doxorubicin Adverse Reactionunknown90
2025-01-31P1/P2SpyGlass Pharma, Inc. SGPNCT06120842 Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionCataract; Glaucoma; Ocular Hypertensionactive not recruiting201
2025-01-31 est.P1/P2Hobart W. HarrisNCT06134843 Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site WoundsSkin Graft Complicationsunknown12
2025-01-31 est.P2RemeGen Co., Ltd.NCT06155383 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.Gastric Cancer; Gastroesophageal Junction Adenocarcinomarecruiting90
2025-01-31P3Viatris Specialty LLC VTRSNCT06215859 Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following HerniorrhaphyAcute Pain; Post Operative Pain; Paincompleted579
2025-01-31 est.P3Pharming Technologies B.V. PHARNCT06249997 An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDSAPDS Gene Mutationunknown3
2025-01-31P3Tris Pharma, Inc.NCT06423703 A Study of Cebranopadol for the Treatment of Acute Pain After BunionectomyAcute Paincompleted240

← 2024-12 | 2025-02 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.